CN107325085A - Citrinin compounds dicitrinone D preparation methods and its application in terms of lymph cancer - Google Patents
Citrinin compounds dicitrinone D preparation methods and its application in terms of lymph cancer Download PDFInfo
- Publication number
- CN107325085A CN107325085A CN201610361184.3A CN201610361184A CN107325085A CN 107325085 A CN107325085 A CN 107325085A CN 201610361184 A CN201610361184 A CN 201610361184A CN 107325085 A CN107325085 A CN 107325085A
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer cell
- penicillium citrinum
- extract
- ibpt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of citrinin compounds dicitrinone D preparation methods and its application in terms of lymph cancer, its structural formula is:.By fermented and cultured Penicillium citrinum (Penicillium citrinum) IBPT-5, fermentate is obtained, the compound is then isolated and purified out from fermentate.It is verified by experiments, the compound has good antitumor activity to people's lymphocytic cancer cell U937, the research of lymph cancer can be used for as lymphocytic cancer cell Proliferation Ability medicine or antineoplastic is prepared.
Description
Technical field
The invention belongs to biomedicine field, and in particular to a kind of citrinin compounds dicitrinone D preparation sides
Method and its application in terms of lymph cancer.
Background technology
Citrinin be citrinin species in the organic compounds containing nitrogen that a class is produced by biological cometabolism, nature compared with
It is many, mostly from plant, therefore there is the title of vegetable soda again.Citrinin has important physiological action to humans and animals, including flat
Antibechic, hypoglycemic, reducing blood lipid, antibacterial, antitumor, analgesia etc. are breathed heavily, wherein being protruded the most with antibacterial, antitumor activity.Natural knot
Structure citrinin is the important sources of discovery lead compound in innovation drug research, has been applied to clinical citrinin medicine at present
Through nearly hundred kinds.Research finds that it is mould that some marine fungis can produce the tangerine that structure is novel, activity is good during cometabolism
Element, with good medicinal and industrialization prospect.
The present inventor studies and learnt, Penicillium citrinum (Penicillium citrinum) IBPT-5, (in 2013 12
The moon is deposited in China typical culture collection center, address on 25th:Wuhan Wuhan University, deposit number is:CCTCC NO:M
2013713) crude extract of tunning has good cell inhibitory effect activity, and its active component is studied then.
Research finds that shown citrinin compounds have antiangiogenic cancer activity, has not yet to see the compound to people's lymphocytic cancer cell
The report of U937 proliferation inhibition activity, therefore in the market is also there is not yet medicine related to this.
The content of the invention
It is an object of the invention to provide a kind of citrinin compounds dicitrinone D preparation methods and its in lymph
Application in terms of cancer, the compound, which has, suppresses lymphocytic cancer cell proliferation function, and with antiangiogenic cancer activity, its structural formula is:
。
The preparation method of the compound, is by fermented and cultured Penicillium citrinum (Penicillium citrinum) IBPT-
5, fermentate is obtained, the compound is then isolated and purified out from fermentate, is comprised the following steps that:
(1)Fermenting and producing
Cultivate microorganism conventional method, take Penicillium citrinum (Penicillium citrinum) IBPT-5 is inoculated into PDA solids
Cultivate 4 days, be then seeded into nutrient solution in 28 DEG C of incubators on slant medium, 28 DEG C of static gas wave refrigerators are obtained after 30 days
Mycelium and zymotic fluid;The nutrient solution composition:Every liter of water containing the g of mannitol 20.0, the g of yeast extract 3.0, the g of maltose 20.0,
The g of monosodium glutamate 10.0, glucose 10.0 g, KH2PO4 0.5 g、MgSO4The 0.3 g and g of NaCl 30.0;
(2)The acquisition of medicinal extract
With gauze by mycelium and separation of fermentative broth, zymotic fluid is extracted twice with the ethyl acetate of two volumes, extract subtracts
Pressure distillation obtains the ethyl acetate extract of zymotic fluid to dry;
(3)The separation and purification of compound
The step(2)After obtained ethyl acetate extract is by 100-200 mesh silica gel mixed samples, with petroleum ether:Dichloromethane:Methanol
Silica gel chromatographic column gradient elution is depressurized for eluent, with dichloromethane:Methanol is eluent, further passes through pressurized silica gel post
Chromatographic grade is eluted, and obtains dichloromethane:Methanol v/v=100:1 eluate, then pass through semi-preparative liquid chromatography (1010 types
ODS-A, 10 × 250 mm, 5 μm):Separation flow velocity is 5 mL/min, and mobile phase is that 85% acetonitrile contains 0.1% TFA, obtains shownization
Compound, tR 6.8 min。
Penicillium citrinum (Penicillium citrinum) IBPT-5, is deposited in China on December 25th, 2013
Type Tissue Collection, address:Wuhan Wuhan University, deposit number is:CCTCC NO:M 2013713.
The present invention also protects described compound preparing the purposes in suppressing lymphocytic cancer cell hyperproliferation agent, and the change
Purposes of the compound in antiangiogenic cancer drug is prepared.The lymphocytic cancer cell behaviour lymphocytic cancer cell U937.
The beneficial effects of the present invention are:The citrinin compound shown in research is more rare, the citrinin class chemical combination
Thing has significant suppression lymphocytic cancer cell proliferation activity, has not yet to see the compound and breeds suppression to people's lymphocytic cancer cell U937
The report of activity is made, therefore in the market is also there is not yet medicine related to this.
Brief description of the drawings:
Fig. 1 is main COSY, HMBC and the NOE signals of compound Dicitrinone D.
Embodiment
Below in conjunction with specific embodiment, the present invention will be further described, but the present invention is not limited only to these embodiments.
The chemical constitution of signified compound in examples below:
。
The fermenting and producing and separation and purification of the compound of embodiment 1
1 fermenting and producing
Produce the fermented and cultured of bacterium:By the conventional method of culture microorganism, Penicillium citrinum (Penicillium citrinum) is taken
IBPT-5 (is deposited in China typical culture collection center, address on December 25th, 2013:Wuhan Wuhan University, protects
Hiding numbering is:CCTCC NO:M 2013713) in right amount, it is inoculated into PDA solid slope culture mediums and is cultivated in 28 DEG C of incubators
4 days.
The inclined-plane culture Penicillium citrinum of 4 days (Penicillium citrinum) appropriate IBPT-5 is taken, is inoculated into and is equipped with
[nutrient solution constitutes (g/l) to 400mL nutrient solutions:Mannitol 20.0, yeast extract 3.0, maltose 20.0, monosodium glutamate 10.0, grape
Sugar 10.0, KH2PO40.5, MgSO40.3, NaCl 30.0 constant volume] 1000mL conical flasks in, 28 DEG C of static gas wave refrigerators 30 days
Afterwards, mycelium and zymotic fluid are obtained.
The acquisition of 2 medicinal extract
With gauze by mycelium and separation of fermentative broth.By zymotic fluid ethyl acetate 1:2 (v/v) are extracted twice, and extract subtracts
Pressure distillation obtains the g of ethyl acetate extract 32.0 of zymotic fluid to dry.
The separation and purification of 3 compounds
After the medicinal extract is by 100-200 mesh silica gel mixed samples, with petroleum ether:Dichloromethane:Methanol is that eluent depressurizes silica gel color
Post gradient elution is composed, 11 components are obtained.Component 3 (1.8 g) (eluate of dichloromethane) is with dichloromethane:Methanol is to wash
De- liquid, further by pressurized silica gel column chromatography gradient elution, obtained subfraction 3-2 (210 mg) (dichloromethane:Methanol
v/v=100:1 eluate), then pass through semi-preparative liquid chromatography (1010 type ODS-A, 10 × 250 mm, 5 μm):Separate flow velocity
For 5 mL/min, mobile phase is that 85% acetonitrile contains 0.1% TFA, obtains shown compound (4.6 mg, tR 6.8 min)。
Compound as white powder, high resolution mass spectrum HRESI-MS existsm/z359.1457 place provide molecular ion peak [M+
H]+, (calcd. for C20H23O6, 359.1489), it is 358 to point out molecular weight, speculates that molecular formula is with reference to spectral information
C20H22O6。1H and13C-NMR data are shown in Table 1, and main COSY, HMBC and NOE signal is shown in Fig. 1.
The NMR compounds of table 11H and13C-NMR data (500MHz1H and 125MHz 13C, in CDCl3)
The test of the anti tumor activity in vitro of embodiment 2
1 laboratory sample and experimental method
The preparation test sample of sample solution is the pure compounds of separation and purification in above-mentioned implementation 1.Precision is weighed in right amount
Sample, the solution of concentration needed for being configured to DMSO, for surveying activity.
The squamous subculture of cell line and cell uses tumor cell line, and tumour cell uses the RPMI 1640 containing 10% FBS to train
Base is supported, at 37 DEG C in being passed through 5% CO2Incubator in squamous subculture.
Cell inhibitory effect activity test method
WST-1 methods are taken the logarithm the lymphocytic cancer cell in growth period, and cell density is adjusted into every milliliter 5 × 104Individual cell, by every hole
100 μ L are inoculated in 96 porocyte culture plates, and 5% CO is passed through in 37 DEG C2Incubator in overnight incubation.Supernatant is sucked, plus
Enter the μ L of culture medium 100 containing sample, continue to cultivate 48 h.10 μ L WST-1 liquid are added per hole, 4 h are cultivated.Utilize Bio-Rad
Company produces 680 type ELIASAs and determined per light absorption value (OD) value of hole at 450nm.Sample is each dense in the orifice plate of same 96
Degree is respectively provided with five holes, separately set five hole blank controls and acellular zeroing hole (if medicine have color to do relative medicine concentration without
Cell returns to zero).Each hole OD values first do corresponding acellular zeroing, then take five hole mean OD values by IR (%)=(ODBlank control-
ODSample)/ODBlank control× 100% formula calculates cell proliferation inhibition rate (IR%) under each concentration.
2. experimental result
Cell inhibitory effect active testing result
In the test of WST-1 methods, according to the lymphocytic cancer cell proliferation inhibition rate of the compound of various concentrations, using SPSS16.0
Software carries out data processing and calculation of half inhibitory concentration IC50Value, the results are shown in Table 2.
The inhibitory activity that the compound of table 2 is bred to people's lymphocytic cancer cell
3. conclusion
The compound has preferable antitumor activity to people's lymphocytic cancer cell U937, can press down as lymphocytic cancer cell propagation is prepared
Pharmacy thing or antineoplastic are used for the research of lymph cancer.
The foregoing is only presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification, should all belong to the covering scope of the present invention.
Claims (6)
1. compound。
2. a kind of preparation method of compound as claimed in claim 1, it is characterised in that:Fermented and cultured Penicillium citrinum IBPT-5, is obtained
Fermentate is taken, the compound, the Penicillium citrinum IBPT-5, on December 25th, 2013 are then isolated and purified out from fermentate
It is deposited in China typical culture collection center, address:Wuhan Wuhan University, deposit number is:CCTCC NO:M
2013713。
3. the preparation method of the compound according to right 2, it is characterised in that:Comprise the following steps that:
(1)Fermenting and producing
The conventional method of microorganism is cultivated, takes Penicillium citrinum IBPT-5 to be inoculated into PDA solid slope culture mediums in 28 DEG C of incubators
Middle culture 4 days, is then seeded into nutrient solution, and 28 DEG C of static gas wave refrigerators obtain mycelium and zymotic fluid after 30 days;The nutrient solution
Composition:Every liter of water containing the g of mannitol 20.0, the g of yeast extract 3.0, the g of maltose 20.0, the g of monosodium glutamate 10.0, the g of glucose 10.0,
KH2PO4 0.5 g、MgSO4The 0.3 g and g of NaCl 30.0;
(2)The acquisition of medicinal extract
With gauze by mycelium and separation of fermentative broth, zymotic fluid is extracted twice with the ethyl acetate of two volumes, extract subtracts
Pressure distillation obtains the ethyl acetate extract of zymotic fluid to dry;
(3)The separation and purification of compound
By step(2)After obtained ethyl acetate extract is by 100-200 mesh silica gel mixed samples, with petroleum ether:Dichloromethane:Methanol
Silica gel chromatographic column gradient elution is depressurized for eluent, with dichloromethane:Methanol is eluent, further passes through pressurized silica gel post
Chromatographic grade is eluted, and obtains dichloromethane:Methanol v/v=100:1 eluate, then pass through the type of semi-preparative liquid chromatography 1010
ODS-A, 10 × 250 mm, 5 μm:Separation flow velocity is 5 mL/min, and mobile phase is that 85% acetonitrile contains 0.1% TFA, obtains shownization
Compound, tR 6.8 min。
4. the compound described in claim 1 is preparing the purposes in suppressing lymphocytic cancer cell hyperproliferation agent.
5. purposes of the compound in antiangiogenic cancer drug is prepared described in claim 1.
6. purposes according to claim 4, it is characterised in that:Described lymphocytic cancer cell behaviour lymphocytic cancer cell U937.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610361184.3A CN107325085B (en) | 2016-05-27 | 2016-05-27 | Citrinin compounds dicitrinone D preparation method and its application in terms of lymph cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610361184.3A CN107325085B (en) | 2016-05-27 | 2016-05-27 | Citrinin compounds dicitrinone D preparation method and its application in terms of lymph cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107325085A true CN107325085A (en) | 2017-11-07 |
CN107325085B CN107325085B (en) | 2019-07-09 |
Family
ID=60193394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610361184.3A Expired - Fee Related CN107325085B (en) | 2016-05-27 | 2016-05-27 | Citrinin compounds dicitrinone D preparation method and its application in terms of lymph cancer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107325085B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104402899A (en) * | 2014-12-18 | 2015-03-11 | 福州大学 | Citrinin compound penicitrinol L derived from Penicillium citrinum, preparation method and application of citrinin compound penicitrinol L |
CN104402898A (en) * | 2014-12-18 | 2015-03-11 | 福州大学 | Citrinin compound penicitrinol M derived from Penicillium citrinum, preparation method and application of citrinin compound penicitrinol M |
CN104447781A (en) * | 2014-12-18 | 2015-03-25 | 福州大学 | Citrinin compound penicitrinol N derived from penicillium citrinum as well as preparation method and application thereof |
CN104478891A (en) * | 2014-12-18 | 2015-04-01 | 福州大学 | Penicillium citrinum sourced citrinin compound (penicitrinol O) as well as preparation method and application thereof |
-
2016
- 2016-05-27 CN CN201610361184.3A patent/CN107325085B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104402899A (en) * | 2014-12-18 | 2015-03-11 | 福州大学 | Citrinin compound penicitrinol L derived from Penicillium citrinum, preparation method and application of citrinin compound penicitrinol L |
CN104402898A (en) * | 2014-12-18 | 2015-03-11 | 福州大学 | Citrinin compound penicitrinol M derived from Penicillium citrinum, preparation method and application of citrinin compound penicitrinol M |
CN104447781A (en) * | 2014-12-18 | 2015-03-25 | 福州大学 | Citrinin compound penicitrinol N derived from penicillium citrinum as well as preparation method and application thereof |
CN104478891A (en) * | 2014-12-18 | 2015-04-01 | 福州大学 | Penicillium citrinum sourced citrinin compound (penicitrinol O) as well as preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN107325085B (en) | 2019-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107298671A (en) | Come from the secalonic acid H of penicillium oxalicum and prepare the application of anti-human colon cancer drug | |
CN103865808B (en) | A kind of anticancer usage of the penicillium sp enol A1 coming from Aspergillus citrimum | |
CN104402898B (en) | Citrinin compounds penicitrinol M coming from Aspergillus citrimum and its preparation method and application | |
CN104592082B (en) | Come from the penicillium sp enol D of Aspergillus citrimum2preparation method and applications | |
CN107298670A (en) | Come from penicillium oxalicum secalonic acid H and prepare anti-human oral cavity epidermoid carcinoma medicinal application | |
CN105061446B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting nasopharyngeal carcinoma | |
CN107298669A (en) | Come from the secalonic acid I of penicillium oxalicum and anti-human oral cavity epidermoid carcinoma medicinal application | |
CN107325087B (en) | Citrinin compounds dicitrinone D and its application in terms of malignant mela noma | |
CN107325085B (en) | Citrinin compounds dicitrinone D preparation method and its application in terms of lymph cancer | |
CN107325088B (en) | Citrinin compounds dicitrinone D preparation method and the application in terms of nasopharyngeal carcinoma | |
CN107325081B (en) | Citrinin compounds dicitrinone D preparation method and its application in terms of lung cancer | |
CN104447475B (en) | Preparation method and application of penicillenol D1 derived from penicillium citrinum | |
CN107325086B (en) | Citrinin compounds dicitrinone D preparation method and its application in terms of colon cancer | |
CN105153175B (en) | The penicitrinine A for coming from Penicillium citrinum and its application for preparing anti-human oesophagus cancer drug | |
CN105153176B (en) | The penicitrinine A for coming from Penicillium citrinum and its application for preparing anti-human lung-cancer medicament | |
CN105061443B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting human liver cancer | |
CN105061444B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting human colorectal carcinoma | |
CN105061445B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting human gastric cancer | |
CN105001228B (en) | Application of penicillium citrinum-derived penicitrinine A in preparing drugs for treating human oral epidermoid tumor | |
CN105131006B (en) | Penicitrinine A sourced from penicillium citrinum and application thereof in preparation of anti-malignant melanoma drug | |
CN105017272B (en) | Penicitrinine A originated from penicillium citrinum and application thereof in preparation of anti human breast cancer drugs | |
CN106491596B (en) | Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma | |
CN106389418B (en) | Derived from tangerine green trichoderma mould enol E1 liver cancer application | |
CN106432034B (en) | Mould enol E1 derived from tangerine green trichoderma is in the application for preparing anti-breast cancer medicines | |
CN109106708A (en) | Derived from penicillium oxalicum 4-4 ' isomerization secalonic acid D liver cancer application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190709 |